Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.74 |
| ▸ | FLT3 | P36888 | 2/20 | 0.69 |
| ▸ | KIT | P10721 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | ITK | Q08881 | 3/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.68 |
| ▸ | TEC | P42680 | 3/20 | 0.67 |
| ▸ | BMX | P51813 | 3/20 | 0.67 |
| ▸ | TXK | P42681 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 2/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.67 |
| ▸ | LATS1 | O95835 | 1/20 | 0.67 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123564 | 1.00 | BTK (0.74) | BTKFLT3KITEGFRITK | |
| SCHEMBL30718180 | 0.95 | BTK (0.68) | BTKFLT3KITEGFRITK | |
| SCHEMBL22720965 | 0.95 | BTK (0.68) | BTKFLT3KITEGFRITK | |
| SCHEMBL15641034 | 0.95 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL1628863 | 0.95 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL30324920 | 0.95 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL29671300 | 0.95 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL12808088 | 0.95 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL17951556 | 0.95 | BTK (0.73) | BTKFLT3KITEGFRITK | |
| SCHEMBL19230406 | 0.94 | BTK (0.77) | BTKFLT3KITEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027041-A | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113544130-B | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
| EP-3978496-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | Haisco Pharmaceuticals Pte. Ltd. (SG) | 2022-04-06 | — | — | EP | disclosed |
| CN-113544130-A | BTK inhibitor ring derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
| US-20170281810-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-10-05 | — | — | US | disclosed |
| US-9717745-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-08-01 | — | — | US | disclosed |
| US-20160324878-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-11-10 | — | — | US | disclosed |
| US-7741330-B1 | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741330-B1 | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | BTK 1/4885FLT3 83/4885KIT 801/4885 |
| US-20170281810-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | BTK, BCL9, BCL9L | BTK 1/4885FLT3 302/4885KIT 1270/4885 |
| US-20160324878-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | BTK, BCL9, BCL9L | BTK 1/4885FLT3 302/4885KIT 1270/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885FLT3 67/4885KIT 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.